The Receptor Study

The study aims to evaluate the safety and efficacy of a potential new treatment for severe neurological conditions that currently have limited treatment options.

The study drug is a first-in-human medication representing a new potential treatment for GRIN-related disorders, which include neurodevelopmental conditions like epilepsy, autism, intellectual disability, and behavioural disorders. The study medication is administered as an oral solution and works by targeting a specific part of the brain's NMDA receptor. The study drug could offer new hope for controlling seizures and improving quality of life for future patients suffering with these conditions.

The results of this study will provide critical data, essential for the development and approval of new therapeutic agents for the wider population across the world.

Clinical Trial Details:

• An independent ethics committee has approved this clinical trial.
• Participants will be reimbursed for their time

Call us on 1300 908 965 to discuss your eligibility today!